Automating Dermatology InterQual Criteria for Biologics and Mohs Surgery

Navigating dermatology InterQual criteria for high-cost biologics and complex procedures like Mohs surgery presents significant administrative burdens. Klivira provides intelligent automation to streamline these critical prior authorization workflows.

For revenue cycle directors and prior authorization coordinators in dermatology, ensuring medical necessity aligns with InterQual criteria is paramount for reimbursement. The complexity of specialty drug step therapy, detailed clinical documentation requirements, and periodic re-authorizations for chronic conditions demand precision and efficiency. Klivira's platform is engineered to address these challenges head-on.

The Role of InterQual in Dermatology Prior Authorization

InterQual, a product of Change Healthcare / Optum, provides evidence-based clinical criteria essential for determining the medical necessity of treatments and procedures. In dermatology, these criteria are applied to high-cost biologics for conditions like psoriasis and atopic dermatitis, as well as specific surgical interventions such as Mohs micrographic surgery. Adhering to InterQual guidelines helps standardize care decisions and ensures appropriate utilization of healthcare resources.

Key Dermatology Procedures and Medications Requiring InterQual Review

Biologics for psoriasis and psoriatic arthritis (e.g., Dupixent, Cosentyx, Tremfya, Skyrizi)
Biologics for atopic dermatitis (e.g., dupilumab, tralokinumab)
Biologics for hidradenitis suppurativa (e.g., adalimumab, secukinumab)
Mohs micrographic surgery for non-melanoma skin cancers
Advanced skin cancer treatments, including immunotherapies
Certain phototherapy regimens, especially home-based treatments

Navigating InterQual Criteria for Dermatology Biologics

Prior authorization for dermatology biologics often involves rigorous InterQual review, referencing guidelines such as those from the AAD. Payers require comprehensive documentation including diagnosis confirmation, severity scores (e.g., PASI, BSA, EASI), and evidence of failed trials of prior topical, phototherapy, or conventional systemic therapies (step therapy). Additionally, pre-biologic screenings for conditions like TB and hepatitis are commonly mandated to meet medical necessity criteria.

InterQual and Mohs Micrographic Surgery

Mohs micrographic surgery frequently triggers InterQual review, particularly for non-melanoma skin cancers in cosmetically or functionally sensitive areas. Documentation must align with AAD Appropriate Use Criteria (AUC) regarding tumor type, size, location, and any prior treatments. Klivira's platform supports AUC validation for Mohs surgery, helping ensure submissions meet these specific criteria and reducing the likelihood of denials.

Streamlining InterQual Submissions in Dermatology with Klivira

Klivira's platform integrates with leading EMRs to automate the collection and submission of clinical documentation required for dermatology InterQual reviews. Our system incorporates AAD-guideline-aware step-therapy logic for biologics and supports periodic re-authorization workflows common in chronic dermatologic care. By intelligently routing medical-vs-pharmacy benefit claims and validating documentation against payer-specific and InterQual criteria, Klivira enhances efficiency and accuracy in prior authorization.

Common InterQual-Related Denial Reasons in Dermatology

Failure to document required step therapy for psoriasis biologics
Mohs AUC mismatch regarding site or tumor type
Insufficient documentation of disease severity (missing PASI, EASI, BSA scores)
Gaps in pre-biologic screening (TB, hepatitis)
Lack of evidence for prior topical or phototherapy trials
Incorrect routing for self-injection vs. clinic infusion (medical vs. pharmacy benefit)

Frequently asked questions

How does Klivira help with step therapy requirements for dermatology biologics?

Klivira's platform incorporates AAD-guideline-aware step-therapy logic. It helps identify and document the required trials of prior topical, phototherapy, or conventional systemic therapies, ensuring these prerequisites are clearly presented in the InterQual submission to support medical necessity.

Can Klivira assist with the periodic re-authorization for chronic dermatology conditions?

Yes, Klivira supports periodic re-authorization workflows for chronic biologic treatments in dermatology, which typically occur on 6 or 12-month cycles. The platform helps manage these recurring submissions, ensuring timely renewals and continuity of care.

What specific documentation does Klivira help gather for Mohs surgery InterQual reviews?

For Mohs surgery, Klivira assists in gathering documentation related to the lesion's site, tumor type, and any prior treatments, validating these against AAD Appropriate Use Criteria. This ensures the submission aligns with InterQual's medical necessity requirements for the procedure.

How does Klivira address the distinction between medical and pharmacy benefits for dermatology drugs?

Klivira's system is designed to intelligently route claims based on whether a biologic is self-injected at home (often pharmacy benefit) or administered via clinic infusion (often medical benefit). This helps ensure the correct payer channel is utilized for InterQual review and submission.

Does Klivira integrate with our existing EMR to support dermatology InterQual workflows?

Yes, Klivira is designed for seamless integration with major EMR systems. This allows for automated extraction of clinical data, such as PASI/BSA scores, diagnosis codes, and treatment history, directly from the EMR to populate InterQual-related prior authorization requests.